Cancer Predisposition

Questions discussed in this category

What adjustments, if any, do you make to chemotherapy regimens for patients with chromosomal breakage disorders who develop malignancy?

Are there particular drugs you avoid or dose-adjustments that are recommended?

1 Answer available

How would you approach breast cancer screening in an adolescent patient with a CDH1 mutation?

0 Answers available

How would you treat a young patient with classical intermediate-risk Hodgkin lymphoma who has an underlying DNA repair-deficiency disorder, such as congenital mismatch repair disorder or ataxia telangiectasia?

How does your treatment approach vary depending on the underlying predisposition?

1 Answer available

Are CHEK2 mutations a contraindication for breast conservation therapy with lumpectomy + RT?

Should patients with moderate penetrance pathogenic variants be managed similar to BRCA patients and consider risk reducing contralateral mastectomy?&...

4 Answers available

When, if ever, would you recommend risk reducing BSO in patients with moderate penetrance breast cancer germline mutations?

Genes such as ATM, CHEK2, PALB2, RAD51C/D, BRIP1 seem to show some potential increased risk of ovarian cancer. Should these patients under prophylacti...

2 Answers available

Would you consider use of PARP inhibitors in patients with metastatic breast cancer with moderate penetrance germline mutations such as CHEK2, ATM, RAD51?

What about a higher penetrance PV such as PALB2? See JCO OGR 8/2021 by @Mark E. Robson discussing management of non-BRCA pathogenic va...

3 Answers available

For which non-BRCA pathogenic germline variants, if any, might you consider recommending chemoprevention with SERM/AI?

In a scenario where patient's other clinical/familial risk does not sufficiently qualify them? See JCO OGR 8/2021 by @Mark E. Robson discussing manag...

3 Answers available

How do you counsel patients on the efficacy of breast cancer risk reduction strategies such as breast MRI surveillance or bilateral mastectomy for those considered high risk by polygenic risk score, pathogenic variants, and/or family history?

Specifically do we know by how much each intervention reduces the risk of developing MBC or increase breast cancer specific as well as overall surviva...

3 Answers available

How do you approach treatment and surveillance of breast cancers in patients carrying germline MUTYH mutation?

1 Answer available